Please login to the form below

Not currently logged in
Email:
Password:

Janssen

This page shows the latest Janssen news and features for those working in and with pharma, biotech and healthcare.

Daily Brief: Trump arrives in London, NICE says no to Darzalex, Pfizer backs down on prices

Daily Brief: Trump arrives in London, NICE says no to Darzalex, Pfizer backs down on prices

England’s cost effectiveness watchdog NICE has issued draft guidance not recommending Janssen's Darzalex (daratumumab) for second line use in multiple myeloma in combination with existing treatments. ... Janssen says it will continue to seek a solution

Latest news

More from news
Approximately 126 fully matching, plus 397 partially matching documents found.

Latest Intelligence

  • A quest for innovative solutions A quest for innovative solutions

    Janssen adds: “We spend a lot of time asking how we, as an organisation, can prepare for this future because it is happening right now. ... There are some really exciting projects out there and we are also partnering with academic institutions to use

  • Pharma deals continue to slide Pharma deals continue to slide

    Cerecor has sold its kappa opioid receptor antagonist in phase 2 to Janssen (J&J) and Xoma has licensed its interleukin 1 beta intellectual property for cardiovascular disease to Novartis plus ... 74.5 (upfront 65). Cerecor (US). J&J/Janssen (US). Asset

  • Deal Watch - May 2017 Deal Watch - May 2017

    An example is the deal between Janssen and the Japanese company Peptidream that has a peptide discovery platform. ... Peptidream (CN). Janssen (US). Licence. Peptide discovery platform. Up to 1, 150.

  • Deal Watch February 2017 Deal Watch February 2017

    Other pharma companies divesting assets this month include Janssen/J&J and Sanofi. ... Joint venture. 286.3. Janssen/ Akebia Therapeutics. HIF-targeting candidates inc AKB-5169 for IBD (pc) plus library of HIF pathway compounds for multiple therapeutic

  • An exciting outlook for pre-approval access and compassionate use An exciting outlook for pre-approval access and compassionate use

    Various projects across the industry are currently underway to establish fair and transparent mechanisms and recommendations on extremely difficult ethical decisions related to early access, including Janssen's independent review panel

More from intelligence
Approximately 5 fully matching, plus 42 partially matching documents found.

Latest appointments

More from appointments
Approximately 3 fully matching, plus 24 partially matching documents found.

Latest from PMHub

  • Adelphi Research UK wins Agency of the Year at BHBIA Conference

    Adelphi, Janssen and Rethink Mental Illness pro-bono work wins BHBIA Best Conference Paper. ... Adelphi were already excited to work with Janssen and Rethink to generate findings around the Mental Health Act to help lobby government changes, but to have

  • Marketing strategy in complex environments

    Marketing strategy in complex environments. Age-old treatment protocols are being replaced with new and innovative treatment paradigms that will revolutionise the healthcare industry for years to come. Kulveer Singh and Mark Assenti talk through

  • Market Access Transformation

    Pfizer. Janssen. Novartis. Roche. Jazz Pharmaceuticals. Amgen. GSK. Nestle. Gilead. BMS.

  • No Voice, No Choice

    The research was commissioned by Rethink Mental Illness and undertaken by Adelphi Research UK, with support from Janssen Cilag Ltd. ... Rachel Medcalf, Managing Director, Adelphi Research UK commented:. “ It’ s great to be involved in this crucial

  • Patient centricity in the Pharma Industry: why now?

    We interviewed Patient executives from Janssen, Sanofi, AbbVie, Teva, UCB and Novartis.

More from PMHub
Approximately 5 fully matching, plus 32 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Weber Shandwick

At Weber Shandwick, engagement has always been the cornerstone of health communications.We make health matter. Health is a basic human...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics